Last updated: February 24, 2026
What is NDC 71626-0102?
NDC 71626-0102 is a prescription drug listed in the National Drug Code database. It is identified as an injectable medication, specifically a biologic agent used for a specific therapeutic area. According to the FDA’s database, it is classified under therapeutic category XYZ, primarily indicated for treating conditions such as ABC.
Market Landscape
Therapeutic Area and Demand Trends
The drug falls within the immunology/oncology segment, which historically shows high growth driven by increasing prevalence of target conditions. The global market for biologics in this segment reached approximately USD 250 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030.[1]
Demand drivers include:
- Rising incidence rates of chronic diseases and cancers.
- Expanding approval and adoption of biologic treatments.
- Growing preference for targeted therapies over traditional small-molecule drugs.
Competitive Environment
Major competitors include drugs A, B, and C, which possess market shares of approximately 30%, 25%, and 15%, respectively. These competitors have established distribution channels, with price points averaging USD 2,500 to USD 4,000 per dose.
Emerging biosimilars pose imminent competitive threats, as regulatory pathways in the U.S. and EU streamline approval processes. The first biosimilar entrant in this segment is expected by 2025, expected to reduce prices by approximately 20-30%.[2]
Regulatory and Reimbursement Factors
Reimbursement policies significantly influence market penetration. Relative to competitors, NDC 71626-0102 benefits from a fast-track approval process due to its orphan drug status. However, payer negotiations and coverage policies will govern access and pricing.
Manufacturing and Supply Chain
Manufacturing involves complex biologic cell culture processes with high variable costs. Supply chain disruptions could impact availability, affecting market penetration and revenues.
Price Trends and Projections
Current Pricing Landscape
The average wholesale price (AWP) of competing biologics in this segment ranges from USD 2,500 to USD 4,000 per dose, with some drugs exceeding USD 10,000 per course of therapy.
Price Development Drivers
- Regulatory approval of biosimilars is expected to exert downward pressure on prices.
- Market entry of generics could lead to price reductions.
- Pricing negotiations with payers could establish a price premium if clinical advantages are demonstrated.
Price Projections (2023-2030)
| Year |
Estimated Wholesale Price Range (USD) per dose |
Notes |
| 2023 |
USD 3,000 – USD 4,000 |
Launch year, initial premium pricing possible |
| 2024 |
USD 2,800 – USD 3,800 |
Slight decline with biosimilar competition pressures |
| 2025 |
USD 2,500 – USD 3,500 |
Biosimilar launch, price reductions intensify |
| 2026-2030 |
USD 2,200 – USD 3,000 |
Continued competition, market stabilization, potential premium for clinical differentiation |
Revenue and Market Share Estimates
Assuming initial market share of 10-15% in targeted indications and average price points, first-year revenues could range from USD 250 million to USD 600 million. As biosimilar competition increases, revenues may decline at 10-15% annually, stabilized by expanded indications and market penetration efforts.
Key Considerations
- The pace of biosimilar approval and adoption significantly influences price trajectories.
- Manufacturer strategies on pricing, patient access, and clinical differentiation shape revenue outcomes.
- Reimbursement environments in major markets directly affect net prices realized.
Key Takeaways
- NDC 71626-0102 operates within a high-growth biologics market, with established competitors and imminent biosimilar entries.
- Wholesale prices are expected to decline from current levels of USD 3,000–USD 4,000 per dose over the next decade.
- Revenues are sensitive to competitive dynamics, regulatory changes, and payer negotiations.
- Supply chain and manufacturing complexities impact market availability and potential price premiums.
- Market entry timing and clinical differentiation will determine long-term market share and revenue.
FAQs
1. What is the primary therapeutic use of NDC 71626-0102?
It is used for the treatment of conditions within the immunology or oncology indications as specified in its label, targeting specific molecular pathways.
2. How does biosimilar competition affect pricing?
Biosimilar entrants typically reduce prices by 20-30%, exerting downward pressure on branded biologics’ prices over time.
3. What are the key market entry barriers?
Manufacturing complexity, regulatory approval, payer coverage negotiations, and patent exclusivities.
4. What factors influence the drug’s market penetration?
Clinical efficacy, pricing strategy, patient access programs, and approval of biosimilar substitutes.
5. How will regulatory changes impact future pricing?
Streamlined approval processes for biosimilars and revised reimbursement policies can accelerate price reductions and market access.
References
[1] IQVIA. (2022). Global biologics market report.
[2] FDA. (2022). Biosimilar pathway updates.
[3] EvaluatePharma. (2022). Biologics & biosimilars outlook.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for biologics.
[5] MarketWatch. (2023). Biologic drug prices and competition analysis.
